order to improve the efficiency of solvent-based paclitaxel and to overcome its drawbacks in terms of safety, a solvent-free formulation has been developed. This work is a review of the albumin-bound paclitaxel data relative to its pharmacodynamic and pharmacokinetic profiles, its therapeutic efficiency and its safety of use. The activity of albumin-bound paclitaxel in phase II and III trials indicates its significant clinical efficiency in the treatment of metastatic breast cancer. In lung and pancreatic cancer and in melanoma, the use of albumin-bound paclitaxel leads to interesting results which require further investigations. Preclinical and clinical studies have shown that albumin-bound paclitaxel is associated with a better tolerance compared to standard paclitaxel.”
“Background: Serious infectious morbidity is high in preterm see more infants. Enteral supplementation of prebiotics eFT508 may reduce the incidence of serious infections, especially infections related to the gastrointestinal tract.
Objective: The objective was to determine the effect of enteral supplementation of a prebiotic mixture consisting of neutral oligosaccharides
((SC)GOS/LCFOS) and acidic oligosaccharides (AOS) on serious infectious morbidity in preterm infants.
Design: In a randomized controlled trial, preterm infants (gestational age < 32 wk and/or birth weight < 1500 g) received enteral supplementation of 80% (SC)GOS/LCFOS and 20% AOS (1.5 g . kg(-1) . d(-1)) or placebo (maltodextrin) between days 3 and 30 of life. Serious infectious morbidity was defined as a culture positive for sepsis, meningitis, pyelonephritis, or pneumonia. The analysis was performed by intention-to-treat and per-protocol, defined as >= 50% supplementation dose during the study period.
Results: selleck chemicals In total, 113 preterm infants were included. Baseline and nutritional characteristics were not different between groups. In the intention-to-treat
analysis, the incidence of >= 1 serious infection, >= 1 serious endogenous infection, or >= 2 serious infectious episodes was not significantly different in the (SC)GOS/LCFOS/AOS-supplemented and placebo groups. In the per-protocol analysis, there was a trend toward a lower incidence of >= 1 serious endogenous infection and >= 2 serious infectious episodes in the (SC)GOS/LCFOS/AOS-supplemented group than in the placebo group (P = 0.09 and P = 0.07, respectively).
Conclusions: Enteral supplementation of (SC)GOS/LCFOS/AOS does not significantly reduce the risk of serious infectious morbidity in preterm infants. However, there was a trend toward a lower incidence of serious infectious morbidity, especially for infections with endogenous bacteria. This finding suggests a possible beneficial effect that should be evaluated in a larger study. This trial was registered at isrctn. org as ISRCTN16211826. Am J Clin Nutr 2010;91:679-86.